Citigroup-Backed HK$4.00 Cash Offer Launched for Wuxi Biologics Shares at 99% Premium
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an announcement.
Citigroup Global Markets Asia will, on behalf of an unnamed offeror, launch a voluntary conditional cash offer for all issued shares of Wuxi Biologics (Cayman) not already owned by the offeror and its concert parties, as well as a related offer to cancel all outstanding share options. The offer is priced at HK$4.00 per share, representing a 99% premium to the company’s last undisturbed closing price of HK$2.01, and is structured as a cash-only proposal that will not be increased, signaling a substantial potential change in ownership and control that could constitute a major transaction for the offeror and a discloseable transaction for Wuxi Biologics, with implications for existing shareholders and the trading of its Hong Kong–listed shares.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$37.36 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) is a contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, providing biologics discovery, development and manufacturing services to global pharmaceutical and biotechnology companies, with a market focus on outsourced biologics production and related solutions.
Average Trading Volume: 30,754,033
Technical Sentiment Signal: Buy
Current Market Cap: HK$155.3B
For an in-depth examination of 2269 stock, go to TipRanks’ Overview page.
